Cyclerion Therapeutics (CYCN) SEC Filings & 10K Form $2.52 -0.05 (-1.75%) Closing price 08/29/2025 03:58 PM EasternExtended Trading$2.46 -0.07 (-2.77%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share SEC Filings Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Recent Cyclerion Therapeutics SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel DateFilerForm TypeView06/18/20253:41 PMCyclerion Therapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 05/15/202511:15 PMCyclerion Therapeutics (Filer)Form EFFECT05/07/20254:25 PMCyclerion Therapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 05/07/20254:21 PMCyclerion Therapeutics (Filer)Form 424B505/06/20253:56 PMCyclerion Therapeutics (Filer)Form S-3Registration statement under Securities Act of 1933 03/28/20258:47 PMCyclerion Therapeutics (Subject)Hecht Peter M (Filed by)Form SCHEDULE 13D/A03/27/20257:38 PMCyclerion Therapeutics (Issuer)Hecht Peter M (Reporting)Form 4Statement of changes in beneficial ownership of securities 03/25/20253:40 PMCyclerion Therapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 02/12/202511:15 PMCyclerion Therapeutics (Filer)Form EFFECT02/12/20252:36 PMCyclerion Therapeutics (Subject)MFN Partners Management, LP (Filed by)Form SCHEDULE 13G/A02/12/202512:25 PMAmerican Endowment Foundation (Filed by)Cyclerion Therapeutics (Subject)Form SCHEDULE 13G/A02/12/20258:28 AMCyclerion Therapeutics (Subject)FMR LLC (Filed by)Form SCHEDULE 13G/A02/04/20253:40 PMCyclerion Therapeutics (Filer)Form S-3Registration statement under Securities Act of 1933 12/17/20247:16 AMCyclerion Therapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/25/20243:05 PMCyclerion Therapeutics (Issuer)Greenspan David Gerald (Reporting)Slate Path Capital LP (Reporting)Form 4Statement of changes in beneficial ownership of securities (Data available from 1/1/2016 forward) Related Companies and Tools Related Companies OnKure Therapeutics SEC Filings Xilio Therapeutics SEC Filings Mural Oncology SEC Filings Reviva Pharmaceuticals SEC Filings Estrella Immunopharma SEC Filings Hyperion DeFi SEC Filings JATT Acquisition SEC Filings SCYNEXIS SEC Filings RenovoRx SEC Filings Tharimmune SEC Filings SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NASDAQ:CYCN) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCN Stock Alerts